The Evolving Triad of Carbapenem Resistance: Emergence of Dominant CRPA, Persistent CRAB, and Rebounding CRKP in a Chinese Regional Hospital (2020-2024)

碳青霉烯类耐药性的演变三联体:中国某地区医院中优势 CRPA 的出现、持续存在的 CRAB 和反弹的 CRKP(2020-2024 年)

阅读:1

Abstract

PURPOSE: Carbapenem-resistant Gram-negative bacteria (CR-GNB) represent a critical threat in healthcare settings. However, their evolving epidemiology in regional hospitals remains poorly understood. We aimed to delineate the resistance trends and risk factors of CR-GNB in a Chinese regional hospital to guide infection control. PATIENTS AND METHODS: We conducted a retrospective epidemiological study from 2020 to 2024. A total of 148,622 clinical specimens were collected, yielding 19,264 culture-positive isolates. We examined microbial distribution and carbapenem resistance (CR) rates. Multivariable logistic regression was used to identify independent risk factors for CR-GNB infection. RESULTS: The overall culture positivity rate was 12.96%. Gram-negative bacilli accounted for 71.7% of the positive isolates. CR analysis revealed a critical shift: Pseudomonas aeruginosa (CRPA) showed a rapid upward trend (25.3% to 39.3%), Acinetobacter baumannii (CRAB) maintained persistently high resistance (>86%), and Klebsiella pneumoniae (CRKP) exhibited a rebounding pattern (36.2% in 2024). Multivariable analysis identified male sex, advanced age (>60 years), and ICU/SICU admission as significant risk factors. In high-burden wards, CRAB and CRKP exhibited extreme resistance (>96%) to multiple first-line agents. CONCLUSION: Our findings reveal a critical shift in the CR-GNB landscape, characterized by the emergence of dominant CRPA alongside persistent CRAB and rebounding CRKP. This "Evolving Triad", entrenched in ICUs, underscores the urgent need for "Proactive Ecological Intervention" strategies. This study provides a crucial epidemiological baseline for regional hospitals.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。